期刊文献+

非那雄胺联合二甲双胍治疗老年良性前列腺增生合并糖尿病效果分析 被引量:3

Effect analysis of finasteride and metformin combination therapy of benign prostatic hyperplasia in elderly diabetic
暂未订购
导出
摘要 目的探讨非那雄胺联合二甲双胍治疗老年良性前列腺增生合并糖尿病的效果。方法75例良性前列腺增生合并糖尿病患者均为2012年4月~2013年9月来我院确诊的病例,采用非那雄胺与二甲双胍联合治疗,比较治疗前后的差异。结果治疗后国际前列腺症状评分、生活质量评分、前列腺体积、前列腺特异性抗原、残余尿量、体质指数及三酰甘油均低于治疗前,最大尿流率高于治疗前,差异有统计学意义(P〈0.05)。结论非那雄胺联合盐酸二甲双胍治疗良性前列腺增生合并糖尿病临床效果较好,两种药物能起到协同作用,可以在临床推广应用。 Objective To investigate the effect of finasteride and combination therapy with metformin in elderly diabetic patients with benign prostatic hyperplasia. Methods Seventy-five cases of benign prostatic hyperplasia patients with diabetes mellitus in this group were selected from April 2012 to September 2013 in our hospital, they used finasteride metformin therapy, the clinical results after and before treatment were compared with statistical methods. Results The international prostate symptom score, quality of life score, prostate volume, prostate-speclfic antigen, residual urine volume, body mass index and triglycerides after treatment were lower than before treatment, the maximum flow rate was higher than before treatment, there were significant difference between after and before treatment (P 〈0.05). Conclusion Finasteride combined metformin hydrochloride for benign prostatic hyperplasia patients with diabetes have better clinical results, the two drugs with synergistic effect can be used in clinical practice.
作者 姚增文
出处 《中国现代医生》 2014年第13期62-64,共3页 China Modern Doctor
关键词 前列腺增生 糖尿病 非那雄胺 二甲双胍 Prostatic hyperplasia Diabetes Finasteride Metformin
  • 相关文献

参考文献11

二级参考文献94

共引文献55

同被引文献29

  • 1Qu x, Huang Z, Meng X, et al. Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients [ J]. Int Urol Nephrol,2014,46(3 ) :499-504.
  • 2Joseph MA, Harlow SD, Wei JT, et al. Risk factors for lower uri- nary tract symptoms in a population-based sample of African-Amer- ican men [ J ]. Am J Epidemio1.2003.157 ( 10 ) : 906 -914.
  • 3中华医学会糖尿病学分会.2013年版中国糖尿病防治指南[M].北京:北京大学医学出版社,2014:8-9.
  • 4Parsons JK, Carter HB, Partin AW, et al. Metabolic factors asso- ciated with benign prostatic hyperplasia [ J ]. J Clin Endocrinol Metab, 2006,91 ( 7 ) : 2562 -2568.
  • 5Hammarsten J, Damber JE, Karlsson M, et al. Insulin and free oestradiol are independent risk factors for benign prostatic hyper- plasia [ J ]. Prostate Cancer Prostatic Dis, 2009,12 ( 2 ) : 160 - 165.
  • 6Kim WT, Yun SJ, Choi YD, et al. Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels[J]. J Korean Med Sci, 2011,26(9) :1214-1218.
  • 7Vikram A, Jena G, Ramarao P. Insulin-resistance and benign prostatic hyperplasia: the connection [ J ]. Eur J Pharmacol, 2010,641 (2-3) :75-81.
  • 8Roehrbom CG, Boyle P, Bergner D, et al. Serum prostate-spe- cific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trim comparing finasteride versus placebo. PLESS Study Group[J]. Urology, 1999,54 (4) :662-669.
  • 9Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety offi- nasteride therapy for benign prostatic hyperplasia: results of a 2- year randomized controlled trial (the PROSPECT study ). PROscar Safety Plus Efficacy Canadian Two year Study [ J ]. CMAJ, 1996,155 C 9 ) : 1251-1259.
  • 10王碧琼,李云祥.非那雄胺对经尿道前列腺等离子体切除术出血的影响[J].医学信息,2011,24(12):3774-3776. 被引量:6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部